News
Hosted on MSN1mon
Vivid Seats says it expects to return to top-line growth in the second half of the yearShares of Vivid Seats (SEAT) were down 3.98% premarket and are off about 19% on a year-to-date basis.
DOP005 Long-term efficacy and safety of mirikizumab treatment for Crohn’s disease: results from the VIVID-2 open-label extension study. J Crohn Colitis. 2025;19(suppl 1):i87-i89. doi:10.1093 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback